PMDA-2022-0063-V263

Type IB variation for application PMDA-2022-0063. Type IB variation: Specification Change for Upadacitimab — routine update

Variation Number
PMDA-2022-0063-V263
Type
Type IB
Application
PMDA-2022-0063
Change
CHG-2022-0263
Status
In Progress
Fee
€709
Submitted
2023-09-20
Approved
—
Description

Type IB variation: Specification Change for Upadacitimab — routine update